# Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.

Study · id `cardio:ct-nct02978040` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02978040](<https://clinicaltrials.gov/study/NCT02978040>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02978040

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 122 participants.

## Technical summary

Registry record NCT02978040. Randomized; single masking; primary purpose treatment. Start 2017-07-04 (actual); primary completion 2019-08-26 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 122 participants (enrolled count; ClinicalTrials.gov record NCT02978040, source copy `cardio:ctgov-nct02978040-2020-02-21`, retrieved 2026-10-26)
- Started: 2017-07-04 (actual) (ClinicalTrials.gov record NCT02978040, source copy `cardio:ctgov-nct02978040-2020-02-21`, retrieved 2026-10-26)
- Primary completion: 2019-08-26 (actual) (ClinicalTrials.gov record NCT02978040, source copy `cardio:ctgov-nct02978040-2020-02-21`, retrieved 2026-10-26)
- Completion: 2019-12-27 (actual) (ClinicalTrials.gov record NCT02978040, source copy `cardio:ctgov-nct02978040-2020-02-21`, retrieved 2026-10-26)
- Countries: Italy; Switzerland (ClinicalTrials.gov record NCT02978040, source copy `cardio:ctgov-nct02978040-2020-02-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02978040-2020-02-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.
- Acronym: FABOLUS-FASTER
- Condition: Coronary Artery Disease
- Condition: STEMI - ST Elevation Myocardial Infarction
- Intervention (Drug): Cangrelor
- Intervention (Drug): Tirofiban
- Intervention (Drug): Prasugrel
- Lead sponsor: Insel Gruppe AG, University Hospital Bern
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry intervention name matches this record: Prasugrel (`cardio:prasugrel`)
- Registry lists this organization as the lead sponsor: Insel Gruppe AG, University Hospital Bern (`cardio:org-insel-gruppe-ag-university-hospital-bern`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial (`cardio:pubmed-32795098`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Prasugrel Intermediate Metabolite Modulates Platelet Inhibition by Negatively Interfering With an Active Metabolite: An Ex Vivo, In Vitro, and In Silico Study (`cardio:pubmed-40109258`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 76c220bdfc36f8eac7d7435cf65042caae5a97bec7fbd76e58f81d868bb04499
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
